One Day In July LLC Makes New $267,000 Investment in Axon Enterprise, Inc $AXON

One Day In July LLC acquired a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 322 shares of the biotechnology company’s stock, valued at approximately $267,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. CVA Family Office LLC increased its holdings in shares of Axon Enterprise by 26.9% during the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 14 shares in the last quarter. LaSalle St. Investment Advisors LLC increased its holdings in shares of Axon Enterprise by 2.1% during the first quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 16 shares in the last quarter. Hemington Wealth Management increased its holdings in shares of Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares in the last quarter. Washington Trust Advisors Inc. increased its holdings in shares of Axon Enterprise by 44.7% during the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 17 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Axon Enterprise by 5.0% during the first quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 18 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Analysts Set New Price Targets

AXON has been the subject of several recent research reports. Wolfe Research initiated coverage on Axon Enterprise in a report on Monday, July 7th. They set an “outperform” rating for the company. Morgan Stanley set a $885.00 target price on Axon Enterprise and gave the company an “overweight” rating in a research report on Friday, July 11th. Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price on the stock in a research report on Tuesday, August 5th. JMP Securities reaffirmed a “market outperform” rating and set a $825.00 target price on shares of Axon Enterprise in a research report on Monday, September 29th. Finally, Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Stock Up 0.6%

AXON stock opened at $759.44 on Thursday. The stock’s fifty day simple moving average is $732.23 and its two-hundred day simple moving average is $730.52. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 1-year low of $422.38 and a 1-year high of $885.91. The stock has a market cap of $59.62 billion, a P/E ratio of 187.52, a P/E/G ratio of 29.32 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business had revenue of $668.54 million for the quarter, compared to analysts’ expectations of $641.77 million. During the same quarter in the previous year, the firm earned $1.20 earnings per share. The business’s revenue was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insiders Place Their Bets

In other Axon Enterprise news, CFO Brittany Bagley sold 5,000 shares of the business’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the transaction, the chief financial officer owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. The trade was a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeffrey C. Kunins sold 7,891 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $750.10, for a total value of $5,919,039.10. Following the completion of the transaction, the insider directly owned 144,538 shares in the company, valued at approximately $108,417,953.80. This represents a 5.18% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 59,932 shares of company stock valued at $45,115,616. 4.40% of the stock is currently owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.